Liu J.Hu H.-H.Chang C.-L.Jen C.-L.Lee M.-H.Lu S.-N.Wang L.-Y.Yuan Q.Xia N.-S.Sugiyama M.Nishida N.Mizokami M.Chen C.-J.PEI-JER CHENYang H.-I.2021-07-032021-07-0320191542-3565https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060096821&doi=10.1016%2fj.cgh.2018.09.037&partnerID=40&md5=256811c4eaa248c37d6cc5fd4329a81ehttps://scholars.lib.ntu.edu.tw/handle/123456789/568322For chronic hepatitis B patients, hepatitis B e antigen (HBeAg) seroclearance signals a transition from an immunologically active phase to an inactive carrier state with a reduction in hepatitis B virus (HBV) DNA levels and a reduced risk of hepatocellular carcinoma (HCC).1 Predictors of HBeAg seroclearance include lower HBV DNA levels, viral genotype, the precore mutation, and higher serum alanine aminotransferase (ALT) levels.2 ? 2019 AGA Institute[SDGs]SDG3hepatitis B core antibody; hepatitis B(e) antigen; hepatitis B antibody; hepatitis B surface antigen; virus DNA; adult; antibody blood level; antibody detection; chronic hepatitis B; cohort analysis; controlled study; female; hepatic clearance; human; incidence; major clinical study; male; middle aged; predictive value; Short Survey; virus load; chronic hepatitis B; enzyme immunoassay; follow up; genetics; genotype; Hepatitis B virus; immunology; metabolism; prognosis; retrospective study; time factor; virology; virus load; DNA, Viral; Follow-Up Studies; Genotype; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunoenzyme Techniques; Prognosis; Retrospective Studies; Time Factors; Viral Loadshort survey10.1016/j.cgh.2018.09.037302678682-s2.0-85060096821